Additional reduction in blood pressure after cholesterol-lowering treatment by statins (lovastatin or pravastatin) in hypercholesterolemic patients using angiotensin-converting enzyme inhibitors (enalapril or lisinopril)

This publication has 19 references indexed in Scilit:

• Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells.
  Journal of Clinical Investigation, 1998
• Responses to endothelium‐dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men
  British Journal of Pharmacology, 1998
• Atherogenic concentrations of native low‐density lipoproteins down‐regulate nitric‐oxide‐synthase mRNA and protein levels in endothelial cells
  European Journal of Biochemistry, 1998
• Simvastatin, an HMG–Coenzyme A Reductase Inhibitor, Improves Endothelial Function Within 1 Month
  Circulation, 1997
• Association between plasma renin activity and metabolic cardiovascular risk factors in essential hypertension
  Journal of Internal Medicine, 1996
• 3-Hydroxy-3-methyl glutaryl coenzyme A reductase inhibition modulates vasopressin-stimulated Ca2+ responses in rat A10 vascular smooth muscle cells.
  Circulation Research, 1994
• Circulating and tissue endothelin immunoreactivity in hypercholesterolemic pigs.
  Circulation, 1993
• Voltage-dependent Ca2+ channels in resistance arteries from spontaneously hypertensive rats.
  Circulation Research, 1993
• Excess membrane cholesterol alters calcium movements, cytosolic calcium levels, and membrane fluidity in arterial smooth muscle cells.
  Circulation Research, 1991
• Report of the Expert Panel on Population Strategies for Blood Cholesterol Reduction. A statement from the National Cholesterol Education Program, National Heart, Lung, and Blood Institute, National Institutes of Health.
  Circulation, 1991